ITGAM and neoplasm: The immune-cell response, as detected by the increase in CD68+ and CD11b+ cells in tumor-site tissues from the various xenografts, supports the hypothesis that IT NanoDoce® administration initiates a chain of events involving both tumor cell death via direct cytotoxic effects and indirect stimulation of effector immune cells.